Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 02, 2015 8:33 PM ET

Biotechnology

Company Overview of Celldex Therapeutics, Inc.

Company Overview

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, as well as in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma. It also has various earlier stage drug candidates in clinical de...

Perryville III Building

Suite 200

53 Frontage Road

Hampton, NJ 08827

United States

156 Employees

Phone:

908-200-7500

Fax:

908-454-1911

Key Executives for Celldex Therapeutics, Inc.

Founder, Chief Executive Officer, President and Director
Age: 53
Total Annual Compensation: $814.1K
Founder, Chief Scientific Officer and Executive Vice President
Age: 56
Total Annual Compensation: $543.0K
Chief Financial Officer, Principal Accounting Officer, Senior Vice President, Treasurer and Secretary
Age: 67
Total Annual Compensation: $419.1K
Chief Medical Officer and Executive Vice President
Age: 51
Total Annual Compensation: $556.4K
Chief Business Officer and Senior Vice President
Age: 59
Total Annual Compensation: $419.6K
Compensation as of Fiscal Year 2014.

Celldex Therapeutics, Inc. Key Developments

Celldex Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Celldex Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $2.2 million against $0.6 million a year ago. Operating loss was $32.8 million against $28.5 million a year ago. Net loss was $32.4 million or $0.33 per basic and diluted share against $28.3 million or $0.32 per basic and diluted share a year ago. The increase in total revenue in the second quarter of 2015 and the six months ended June 30, 2015 was primarily due to clinical trial collaboration with Bristol-Myers Squibb and research and development agreement with Rockefeller University.   For the six months, the company reported total revenue of $2.7 million against $1.0 million a year ago. Operating loss was $63.7 million against $60.0 million a year ago. Net loss was $62.5 million or $0.65 per basic and diluted share against $58.2 million or $0.65 per basic and diluted share a year ago.

Celldex Therapeutics, Inc. to Report Q2, 2015 Results on Aug 10, 2015

Celldex Therapeutics, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 10, 2015

Celldex Therapeutics, Inc., Q2 2015 Earnings Call, Aug 10, 2015

Celldex Therapeutics, Inc., Q2 2015 Earnings Call, Aug 10, 2015

Similar Private Companies By Industry

Company Name Region
Padlock Therapeutics, Inc. United States
AB Advanced Genetic Analysis Corporation United States
NanoInjection Technologies, LLC United States
Genteric, Inc. United States
Evogene, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Celldex Therapeutics, Inc., please visit www.celldextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.